Skip to content
2000
image of The Pharmacokinetic and Pharmacodynamic Drug-drug Interaction Potential of Cannabidiol

Abstract

Although Cannabidiol (CBD) has recently been approved for use in some neurological diseases, the pharmacology of CBD is not fully understood. reports suggest CBD inhibits a large number of enzymes, generating the possibility of multiple interactions. The aim is to describe the main known interactions, evidence, and actual risk in clinical practice. Existing indexed publications and product monographs were reviewed. The authors cataloged and classified the information based on the severity of the interaction, type (Pharmacokinetic Pharmacodynamic), and level of evidence.

1,289 drug-drug interactions were identified (634 pharmacokinetic and 655 pharmacodynamic interactions). There were a total of 19 major interactions (colchicine, levomethadyl acetate, Mipomersen, propoxyphene, brexanolone, buprenorphine, esketamine, fezolinetant, ketamine, leflunomide, levoketoconazole, lomitapide, morphine, pexidartinib, pralsetinib, relugolix, sodium oxybate, teriflunomide, venetoclax), 393 moderate interactions, 49 minor interactions, and 828 of unknown significance. Drugs that should be avoided in the presence of cannabidiol, those that should be monitored, and those interactions that, while frequently mentioned, do not present sufficient evidence to recommend therapeutic changes are identified. The information highlights the need for caution. While many interactions have been postulated, only a small group warrants consideration in clinical practice. For the remaining drugs, special caution is needed. The long history of human use of the cannabis plant is often confused with the limited timeframe for scientific study of its isolated derivatives. The available information allows us to identify drugs with potential Drug-Drug Interactions of varying severity. This information can be used to improve treatment safety.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/dmb/10.2174/0118723128411684251029100517
2025-11-19
2026-01-05

  • From This Site

    /content/journals/dmb/10.2174/0118723128411684251029100517
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kocis P.T. Vrana K.E. Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions. Med. Cannabis Cannabinoids 2020 3 1 61 73 10.1159/000507998 34676340
    [Google Scholar]
  2. Qian Y. Gurley B.J. Markowitz J.S. The potential for pharmacokinetic interactions between cannabis products and conventional medications. J. Clin. Psychopharmacol. 2019 39 5 462 471 10.1097/JCP.0000000000001089 31433338
    [Google Scholar]
  3. Sharma P. Murthy P. Bharath M.M. Chemistry, metabolism, and toxicology of cannabis: Clinical implications. Iran J. Psychiatry 2012 7 4 149 156 23408483
    [Google Scholar]
  4. Zou S. Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci. 2018 19 3 833 10.3390/ijms19030833 29533978
    [Google Scholar]
  5. Baron E.P. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: What a long strange trip it’s been…. Headache 2015 55 6 885 916 10.1111/head.12570 26015168
    [Google Scholar]
  6. Kaur R. Ambwani S.R. Singh S. Endocannabinoid system: A multi-facet therapeutic target. Curr. Clin. Pharmacol. 2016 11 2 110 117 10.2174/1574884711666160418105339 27086601
    [Google Scholar]
  7. ElSohly M.A. Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005 78 5 539 548 10.1016/j.lfs.2005.09.011 16199061
    [Google Scholar]
  8. Laprairie R.B. Bagher A.M. Kelly M.E.M. Denovan-Wright E.M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor. Br J. Pharmacol. 2015 172 20 4790 4805 10.1111/bph.13250 26218440
    [Google Scholar]
  9. Thomas A. Baillie G.L. Phillips A.M. Razdan R.K. Ross R.A. Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro. Br J. Pharmacol. 2007 150 5 613 623 10.1038/sj.bjp.0707133 17245363
    [Google Scholar]
  10. Pertwee R.G. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin. Br J. Pharmacol. 2008 153 2 199 215 10.1038/sj.bjp.0707442 17828291
    [Google Scholar]
  11. Ibeas Bih C. Chen T. Nunn A.V.W. Bazelot M. Dallas M. Whalley B.J. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 2015 12 4 699 730 10.1007/s13311‑015‑0377‑3 26264914
    [Google Scholar]
  12. Zhornitsky S. Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel) 2012 5 5 529 552 10.3390/ph5050529 24281562
    [Google Scholar]
  13. Iffland K. Grotenhermen F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017 2 1 139 154 10.1089/can.2016.0034 28861514
    [Google Scholar]
  14. van de Donk T. Niesters M. Kowal M.A. Olofsen E. Dahan A. van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain 2019 160 4 860 869 10.1097/j.pain.0000000000001464 30585986
    [Google Scholar]
  15. Khoury J.M. Neves M.C.L. Roque M.A.V. Queiroz D.A.B. Corrêa de Freitas A.A. de Fátima Â. Moreira F.A. Garcia F.D. Is there a role for cannabidiol in psychiatry? World J. Biol. Psychiatry 2019 20 2 101 116 10.1080/15622975.2017.1285049 28112021
    [Google Scholar]
  16. Lauckner J.E. Jensen J.B. Chen H.Y. Lu H.C. Hille B. Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad. Sci. USA 2008 105 7 2699 2704 10.1073/pnas.0711278105 18263732
    [Google Scholar]
  17. Sylantyev S. Jensen T.P. Ross R.A. Rusakov D.A. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad. Sci. USA 2013 110 13 5193 5198 10.1073/pnas.1211204110 23472002
    [Google Scholar]
  18. Kaplan J.S. Stella N. Catterall W.A. Westenbroek R.E. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad. Sci. USA 2017 114 42 11229 11234 10.1073/pnas.1711351114 28973916
    [Google Scholar]
  19. Ohlsson A. Lindgren J.E. Andersson S. Agurell S. Gillespie H. Hollister L.E. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biol. Mass Spectrom. 1986 13 2 77 83 10.1002/bms.1200130206 2937482
    [Google Scholar]
  20. Carrier E.J. Auchampach J.A. Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc Natl Acad. Sci. USA 2006 103 20 7895 7900 10.1073/pnas.0511232103 16672367
    [Google Scholar]
  21. Holland M.L. Allen J.D. Arnold J.C. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur. J. Pharmacol. 2008 591 1-3 128 131 10.1016/j.ejphar.2008.06.079 18619955
    [Google Scholar]
  22. Holland M.L. Panetta J.A. Hoskins J.M. Bebawy M. Roufogalis B.D. Allen J.D. Arnold J.C. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem. Pharmacol. 2006 71 8 1146 1154 10.1016/j.bcp.2005.12.033 16458258
    [Google Scholar]
  23. Zhu H.J. Wang J.S. Markowitz J.S. Donovan J.L. Gibson B.B. Gefroh H.A. DeVane C.L. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J. Pharmacol. Exp. Ther. 2006 317 2 850 857 10.1124/jpet.105.098541 16439618
    [Google Scholar]
  24. Auzmendi J. Palestro P. Blachman A. Gavernet L. Merelli A. Talevi A. Calabrese G.C. Ramos A.J. Lazarowski A. Cannabidiol (CBD) inhibited rhodamine-123 efflux in cultured vascular endothelial cells and astrocytes under hypoxic conditions. Front. Behav. Neurosci. 2020 14 32 10.3389/fnbeh.2020.00032 32256321
    [Google Scholar]
  25. Feinshtein V. Erez O. Ben-Zvi Z. Erez N. Eshkoli T. Sheizaf B. Sheiner E. Huleihel M. Holcberg G. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ 2013 1 e153 10.7717/peerj.153 24058883
    [Google Scholar]
  26. Showing BioInteractions for cannabidiol (DB09061). Available from:https://go.drugbank.com/drugs/DB09061/biointeractions #target-tab.
  27. Balachandran P. Elsohly M. Hill K.P. Cannabidiol interactions with medications, illicit substances, and alcohol: A comprehensive review. J. Gen. Intern. Med. 2021 36 7 2074 2084 10.1007/s11606‑020‑06504‑8 33515191
    [Google Scholar]
  28. Holland M.L. Lau D.T.T. Allen J.D. Arnold J.C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids. Br J. Pharmacol. 2007 152 5 815 824 10.1038/sj.bjp.0707467 17906686
    [Google Scholar]
  29. Feinshtein V. Erez O. Ben-Zvi Z. Eshkoli T. Sheizaf B. Sheiner E. Holcberg G. Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: An ex vivo study. Am. J. Obstet. Gynecol. 2013 209 6 573.e1 573.e15 10.1016/j.ajog.2013.08.005 23933222
    [Google Scholar]
  30. Harvey D.J. Mechoulam R. Metabolites of cannabidiol identified in human urine. Xenobiotica 1990 20 3 303 320 10.3109/00498259009046849 2336840
    [Google Scholar]
  31. Jiang R. Yamaori S. Takeda S. Yamamoto I. Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011 89 5-6 165 170 10.1016/j.lfs.2011.05.018 21704641
    [Google Scholar]
  32. Nye J.S. Seltzman H.H. Pitt C.G. Snyder S.H. High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5′-trimethylammonium delta 8-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 1985 234 3 784 791 10.1016/S0022‑3565(25)23705‑3 2993595
    [Google Scholar]
  33. Mazur A. Lichti C.F. Prather P.L. Zielinska A.K. Bratton S.M. Gallus-Zawada A. Finel M. Miller G.P. Radomińska-Pandya A. Moran J.H. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab. Dispos 2009 37 7 1496 1504 10.1124/dmd.109.026898 19339377
    [Google Scholar]
  34. Radominska-Pandya A. Mazur A. Lichti C.F. Gallus-Zawada A. Zielinska A.K. Bratton S.M. Moran J.H. Human hepatic and extrahepatic UDP‐glucuronosyltransferase (UGTs) enzymes involved in the metabolism of cannabinoids. FASEB J. 2008 22 S1 711 10.1096/fasebj.22.1_supplement.711.4
    [Google Scholar]
  35. Epidiolex. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
  36. Yamaori S. Kinugasa Y. Jiang R. Takeda S. Yamamoto I. Watanabe K. Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Life Sci. 2015 136 87 93 10.1016/j.lfs.2015.07.007 26187180
    [Google Scholar]
  37. Yamaori S. Kushihara M. Yamamoto I. Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem. Pharmacol. 2010 79 11 1691 1698 10.1016/j.bcp.2010.01.028 20117100
    [Google Scholar]
  38. Yamaori S. Koeda K. Kushihara M. Hada Y. Yamamoto I. Watanabe K. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab. Pharmacokinet 2012 27 3 294 300 10.2133/dmpk.DMPK‑11‑RG‑107 22166891
    [Google Scholar]
  39. Jiang R. Yamaori S. Okamoto Y. Yamamoto I. Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab. Pharmacokinet 2013 28 4 332 338 10.2133/dmpk.DMPK‑12‑RG‑129 23318708
    [Google Scholar]
  40. Yamaori S. Ebisawa J. Okushima Y. Yamamoto I. Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011 88 15-16 730 736 10.1016/j.lfs.2011.02.017 21356216
    [Google Scholar]
  41. Yamaori S. Okamoto Y. Yamamoto I. Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab. Dispos 2011 39 11 2049 2056 10.1124/dmd.111.041384 21821735
    [Google Scholar]
  42. Al Saabi A. Allorge D. Sauvage F.L. Tournel G. Gaulier J. Marquet P. Picard N. Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab. Dispos 2013 41 3 568 574 10.1124/dmd.112.047878 23230132
    [Google Scholar]
  43. Shankar P. VigiAccess: Promoting public access to VigiBase. Indian J. Pharmacol. 2016 48 5 606 607 10.4103/0253‑7613.190766 27721554
    [Google Scholar]
  44. Meissner H. Cascella M. Cannabidiol (CBD) in Clinical Care. StatPearls. Treasure Island, FL StatPearls Publishing 2025
    [Google Scholar]
  45. Cannabidiol (CBD) 2024 Available from:https://www.drugs.com/cannabidiol.html
  46. Almeida S.M. Gama C.S. Akamine N. The prevalence and the classification of drug drug interactions in intensive care patients. Einstein 2007 5 4 347 351
    [Google Scholar]
  47. PDR by ConnectiveRx Available from:https://www.pdr.net/
  48. So G.C. Lu J.B.L. Koyama S. Cheng Y.H. Gisch D.L. McClara K. Dexter P.R. Sharfuddin A.A. Etkins J. Tillman E.M. Beamon T.R. Cowsert Z. Stuart J.S. Desta Z. Eadon M.T. A phase I trial of the pharmacokinetic interaction between cannabidiol and tacrolimus. Clin. Pharmacol. Ther. 2025 117 3 716 723 10.1002/cpt.3504 39601108
    [Google Scholar]
  49. Ferretti M.L. Gustin N.D. Sokol C.M. Zamarripa C.A. Feldner M.T. Bonn-Miller M.O. Irons J.G. A preliminary investigation of the simultaneous effects of cannabidiol and caffeine. Exp. Clin. Psychopharmacol. 2024 32 4 475 484 10.1037/pha0000691 37917507
    [Google Scholar]
  50. Zheng T. BouSaba J. Taylor A. Dilmaghani S. Busciglio I. Carlson P. Torres M. Ryks M. Burton D. Harmsen W.S. Camilleri M. A randomized, controlled trial of efficacy and safety of cannabidiol in idiopathic and diabetic gastroparesis. Clin. Gastroenterol. Hepatol. 2023 21 13 3405 3414.e4 10.1016/j.cgh.2023.07.008 37482172
    [Google Scholar]
  51. Wray L. Berwaerts J. Critchley D. Hyland K. Chen C. Thai C. Tayo B. Pharmacokinetic drug‐drug interaction with coadministration of cannabidiol and everolimus in a phase 1 healthy volunteer trial. Clin. Pharmacol. Drug Dev. 2023 12 9 911 919 10.1002/cpdd.1262 37132402
    [Google Scholar]
  52. Thai C. Tayo B. Critchley D. A phase 1 open‐label, fixed‐sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 probe caffeine in healthy subjects. Clin. Pharmacol. Drug Dev. 2021 10 11 1279 1289 10.1002/cpdd.950 33951339
    [Google Scholar]
  53. Watkins P.B. Church R.J. Li J. Knappertz V. Cannabidiol and abnormal liver chemistries in healthy adults: Results of a phase I clinical trial. Clin. Pharmacol. Ther. 2021 109 5 1224 1231 10.1002/cpt.2071 33022751
    [Google Scholar]
  54. VanLandingham K.E. Crockett J. Taylor L. Morrison G. A phase 2, double‐blind, placebo‐controlled trial to investigate potential drug‐drug interactions between cannabidiol and clobazam. J. Clin. Pharmacol. 2020 60 10 1304 1313 10.1002/jcph.1634 32652616
    [Google Scholar]
  55. Perkins D. Butler J. Ong K. Nguyen T.H. Cox S. Francis B. Mcintosh M. Lilley B. A phase 1, randomised, placebo-controlled, dose escalation study to investigate the safety, tolerability and pharmacokinetics of cannabidiol in fed healthy volunteers. Eur. J. Drug Metab. Pharmacokinet 2020 45 5 575 586 10.1007/s13318‑020‑00624‑6 32409982
    [Google Scholar]
  56. Ben-Menachem E. Gunning B. Arenas Cabrera C.M. VanLandingham K. Crockett J. Critchley D. Wray L. Tayo B. Morrison G. Toledo M. A phase II randomized trial to explore the potential for pharmacokinetic drug–drug interactions with stiripentol or valproate when combined with cannabidiol in patients with epilepsy. CNS Drugs 2020 34 6 661 672 10.1007/s40263‑020‑00726‑4 32350749
    [Google Scholar]
  57. Guidelines for ATC classification and DDD assignment. 2024 Available from:https://atcddd.fhi.no/filearchive/publications/2025_guidelines__final_web.pdf
/content/journals/dmb/10.2174/0118723128411684251029100517
Loading
The Pharmacokinetic and Pharmacodynamic Drug-drug Interaction Potential of Cannabidiol
Bentham Science Publishers ; https://doi.org/10.2174/0118723128411684251029100517
/content/journals/dmb/10.2174/0118723128411684251029100517
/content/journals/dmb/10.2174/0118723128411684251029100517
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: drug-drug interactions ; adverse reactions ; therapeutic monitoring ; pharmacovigilance ; Cannabidiol ; pharmacokinetics
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test